CYTO-NK-301

N/A

Report date: 2022/09/06 18:03:54

Base Information

Drug NameCYTO-NK-301
Drug Alias NameCYTO-NK-301
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsB-cell maturation protein modulators +[4] 
TargetsB-cell maturation proteinNKG2D ligands
Therapy Area/IndicationsLeukemia, Myeloid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCytoImmune Therapeutics IncCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesCity Of Hope National Medical CenterCytoImmune Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A